We describe the analytic validation of NeXT Dx, a comprehensive genomic profiling assay to
aid therapy and clinical trial selection for patients diagnosed with solid tumor cancers …

We developed and analytically validated a comprehensive genomic profiling (CGP) assay,
GEM ExTra, for patients with advanced solid tumors that uses Next Generation Sequencing …

Timely and accurate identification of molecular alterations in solid tumors is essential for
proper management of patients with advanced cancers. This has created a need for rapid …

Massively parallel sequencing approaches are beginning to be used clinically to
characterize individual patient tumors and to select therapies based on the identified …

We developed and validated a clinical whole-genome and transcriptome sequencing
(WGTS) assay that provides a comprehensive genomic profile of a patient's tumor. The …

The detection of driver oncogenic variants and the recent identification of tumor-agnostic
genomic biomarkers has driven the use of comprehensive genomic profiling (CGP) for …

We developed and clinically validated a hybrid capture next generation sequencing assay to
detect somatic alterations and microsatellite instability in solid tumors and hematologic …

Background Personalized targeted therapies have transformed management of several
solid tumors. Timely and accurate detection of clinically relevant genetic variants in tumor is …

The development of targeted therapies for both germline and somatic DNA mutations has
increased the need for molecular profiling assays to determine the mutational status of …

Whole-genome sequencing either alone or in combination with whole-transcriptome
sequencing has started to be used to analyze clinical tumor samples to improve diagnosis …